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TREATMENT COST OF FEBRILE NEUTROPENIA (FN) IN
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OBJECTIVES: To assess treatment patterns, resource consump-
tion, and costs related to febrile neutropenia in patients with
acute leukemia receiving chemotherapy (CT) or in ASCT recipi-
ents. METHODS: A multicentre observational cost study was
conducted in 4 academic hospitals. Interim results are presented
for consecutive adult patients receiving CT or ASCT between
January and November 2006. FN is deﬁned as absolute neutro-
phil count <0.5 ¥ 109/L, fever 38°C and no hint of a non-
infectious fever origin. Resource use was extracted from medical
patient charts. FN related costs for medication, diagnostics,
blood products and re-hospitalization are presented from a hos-
pital provider perspective. Costs for prolonged inpatient stay
due to FN are excluded (under investigation). RESULTS: Of 86
patients, 46 received CT and 40 ASCT. Most common disease
in CT pts was AML (78%) and in ASCT pts multiple myeloma
(50%) and NHL (40%). Mean  SD age was 55  17 yrs (CT)
and 57  11 yrs (ASCT). A total of 96% (CT) and 98%
(ASCT) of cases respectively received neutropenia/infection pro-
phylaxes (G-CSF, GM-CSF, antiinfectives). Mean onset of FN
was 12.2  4.6 and 6.8  2.7 days following start of CT or
ASCT. Mean duration of FN episodes was 5.7  4.8 days (CT)
and 3.7  2.3 days (ASCT); mean treatment duration of FN
was 13.3  8.2 days (CT) and 9.2  3.2 days (ASCT). A total
of 91% (CT) and 95% (ASCT) of patients received antibiotics,
46% (CT) and 28% (ASCT) antifungal agents, and 83% (CT)
and 85% (ASCT) blood products. Mean treatment cost per FN
episode was €4,740  6,914 (Range: 0–32,455) for CT cases
and €1,656  1,225 (range: 0–5,721) for ASCT cases. Main
cost drivers were anti-infective drugs which accounted for 62%
of cost in CT patients, and 43% of cost in ASCT patients.
CONCLUSIONS: FN induces signiﬁcant costs in German hos-
pitals with highest average cost for patients with AL receiving
chemotherapy.
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OBJECTIVES: This study examines factors associated with
health care costs among working age patients with diabetic neu-
ropathic pain (DNP) who are undergoing duloxetine therapy.
METHODS: Using a retrospective cohort design and claims
data, we assessed the predictors of total health care costs over a
one-year follow-up period for patients (18–64 years) with 30+
days of available duloxetine therapy between October 1, 2004
and December 31, 2005. The index date was deﬁned as the ﬁrst
observed pharmacy claim for duloxetine. All individuals selected
had 1+ diabetic neuropathy diagnosis and pain medication dis-
pensed in the 12 months pre-index. Two cohorts of patients were
constructed for individuals with a starting duloxetine dose of 30
(“Dulox30”) and 60 (“Dulox60”) milligrams, respectively. Base-
line demographic and clinical characteristics were assessed for
each cohort, as was prior use of pain medications. Resource
utilization and expenditures were evaluated over 12-months
following index. Multivariate linear regression was performed
to assess whether initial dose of duloxetine was correlated with
health care costs, controlling for demographic and clinical char-
acteristics. RESULTS: We identiﬁed 196 Dulox30 patients and
655 Dulox60 patients. The Dulox30 and Dulox60 groups were
similar by age (55.0 vs 54.2, p = 0.16), and gender (59.2% vs.
58.4% female, p = 0.85). A higher proportion of patients in
Dulox30 group had 4+ diabetes-related complications (26.5% vs
18.4%, p < 0.01) and a Charlson Comorbidity score > 1 (23.0%
vs 17.6%, p = 0.03) relative to those in the Dulox60 group. Prior
use of antidepressants was greater among Dulox60 patients
whereas Dulox30 patients were more likely to receive oxycodone
and hydrocodone (all p < 0.01). After adjusting for patient char-
acteristics, patients in both cohorts had similar total health care
costs (p = 0.95). Factors associated with increased costs included
advancing age, prior pain-related hospitalizations, insulin
therapy, diabetes-related complications, and other chronic
comorbidities. CONCLUSIONS: These ﬁndings indicate that
one-year health care costs were similar for DNP patients receiv-
ing duloxetine therapy, regardless of initial dose.
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OBJECTIVES: Fabry-Anderson disease (a-galactosydase A deﬁ-
ciency) is a rare, x-linked lysosomal storage disorder that can
cause early death from renal, cardiac and cerebrovascular
involvement. The speciﬁc treatment currently available for
Fabry-Anderson disease consists of intravenous enzymatic
replacement therapy (ERT) every 2 weeks of the enzyme
a-galactosidase A. The aim of the study was to evaluate the
economic impact of the Fabry-Anderson Disease treatment.
METHODS: The study was a naturalistic, longitudinal retro-
spective Cost of Treatment study. Patients were enrolled during
the 2001–2004 period and followed until 2007. Direct health
care resources attributable to disease management (drugs, ambu-
latory care, day case treatments, hospitalizations, specialist
visits, diagnostics and laboratory exams) were quantiﬁed using
National Health Service (NHS) tariffs expressed in Euro 2008.
NHS perspective was adopted. Health-related quality of life
information were also collected using SF-36 questionnaire at the
enrolment and after 2 and 5 years of treatment. METHODS: T
RESULTS: We enrolled 15 patients (males 53.3%, mean age of
40.27  14.76 y.o.) from the Nephrology Department of the
University “Federico II” of Naples, with a mean follow-up of
5.53  1.13 years. The average monthly cost of care as
€22,536.46  €2,247.93 per patient, mainly because of treat-
ment products. ERT therapy represented 96.2% of the expenses.
SF-36 results showed a signiﬁcant improvement in all the
domains in particular in the physical domains. CONCLUSIONS:
This is the ﬁrst study evaluating the socio-economic impact of
Fabry-Anderson Disease treatment in Italy. This study showed
that this rare disease requires large amounts of resources for the
management, but it also demonstrated that effective care pro-
vides a satisfactory quality of life. To the best of our knowledge
this seems to be the highest cost of treatment.
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